# LYL1

## Overview
LYL1 is a gene that encodes a protein belonging to the basic helix-loop-helix (bHLH) family of transcription factors, which are pivotal in regulating gene expression during hematopoiesis and angiogenesis. The LYL1 protein, characterized by its bHLH domain, forms heterodimeric complexes with other class I HLH proteins, such as E2a, to modulate the transcription of target genes in hematolymphoid and endothelial cells (Deleuze2012Angiopoietin2; Miyamoto1996HelixLoopHelix). It plays a significant role in the development of B lymphocytes and the regulation of the Angiopoietin-2 gene, which is crucial for angiogenesis (Deleuze2012Angiopoietin2; Miyamoto1996HelixLoopHelix). Dysregulation of LYL1 is implicated in various hematological malignancies, including acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), where it contributes to oncogenic processes and may serve as a potential therapeutic target (Nagel2010Multiple; Fang2022Superenhancer).

## Structure
The LYL1 protein is a member of the basic helix-loop-helix (bHLH) transcription factor family, characterized by a conserved bHLH domain that facilitates dimerization and DNA binding. This domain consists of two alpha-helices connected by a loop, which is crucial for its function as a transcriptional regulatory factor (Choudhury2023InSilico; Miyamoto1996HelixLoopHelix). The bHLH domain allows LYL1 to form heterodimeric complexes with E2a proteins, such as E12 and E47, which are essential for its distinctive DNA-binding properties (Miyamoto1996HelixLoopHelix).

LYL1 interacts with other proteins through its N-terminal domain, notably with CREB1, a transcription factor involved in acute myelogenous leukemia (AML). This interaction recruits histone acetyl-transferases p300 and CBP, influencing transcription activation without requiring CREB1 Ser133 phosphorylation (SanMarina2008Lyl1). The LYL1 protein does not homodimerize, indicating its reliance on heterodimerization for functional activity (Miyamoto1996HelixLoopHelix).

The molecular structure of LYL1 includes specific DNA-binding preferences, with the LYL1-E2a heterodimer showing a unique binding site preference, similar to that of E47-TAL1 due to sequence identity in their bHLH regions (Miyamoto1996HelixLoopHelix). The protein's expression patterns and interactions suggest a role in hematopoietic lineage development and leukemogenesis (Miyamoto1996HelixLoopHelix).

## Function
LYL1 is a transcription factor involved in various molecular processes crucial for hematopoiesis. It is part of the basic helix-loop-helix (bHLH) family and forms heterodimeric complexes with class I HLH proteins, such as E2a, to regulate gene expression in hematolymphoid cells (Miyamoto1996HelixLoopHelix). LYL1 is expressed in several hematopoietic lineages, particularly in B lymphocytes, where it may play a role in B-cell development (Miyamoto1996HelixLoopHelix).

In endothelial cells, LYL1 is involved in the transcriptional regulation of the Angiopoietin-2 (ANG-2) gene. It forms complexes with TAL1, LMO2, and GATA2, contributing to the regulation of genes involved in angiogenesis and lymphangiogenesis (Deleuze2012Angiopoietin2). LYL1's role in endothelial cells includes forming homodimers and heterodimers that enhance ANG-2 transcription, which is crucial during angiogenic activation (Deleuze2012Angiopoietin2).

In the context of primitive erythropoiesis, LYL1 can compensate for the loss of SCL in hematopoietic stem cells, maintaining their function once hematopoiesis is established. However, it cannot fully compensate for SCL in primitive erythropoiesis, as demonstrated by the failure of double knockout embryos lacking both SCL and LYL1 (Chiu2018A).

## Clinical Significance
The LYL1 gene is implicated in several hematological malignancies due to its dysregulation. In pediatric acute myeloid leukemia (AML), LYL1 is associated with super-enhancers, which are crucial for the growth and survival of AML cells. The gene's expression is significantly downregulated by the BRD4 inhibitor GNE-987, suggesting its potential as a therapeutic target in AML treatment (Fang2022Superenhancer). In T-cell acute lymphoblastic leukemia (T-ALL), LYL1 is ectopically expressed in certain cell lines, often due to microdeletions upstream of the gene or interactions with transcription factors like HOXA10, LMO2, and NKX2-5. These alterations contribute to the oncogenic network in T-ALL, highlighting LYL1's role in leukemogenesis (Nagel2010Multiple).

LYL1 overexpression is also linked to the expansion of hematopoietic progenitors, promoting cell proliferation and reducing apoptosis, which may support leukemia formation. This overexpression is associated with a stem-like leukemia phenotype and poor prognosis in acute myeloblastic leukemia (AML) (Lukov2011The). These findings underscore the clinical significance of LYL1 in various leukemias, making it a potential marker for therapy resistance and a target for therapeutic intervention.

## Interactions
LYL1 is a basic helix-loop-helix (bHLH) transcription factor that participates in various protein interactions, primarily forming heterodimeric complexes. In hematolymphoid cells, LYL1 interacts with E2a proteins, such as E12 and E47, to form heterodimers. These interactions are facilitated by the helix-loop-helix motifs of both LYL1 and E2a proteins, which are necessary for their dimerization and subsequent DNA-binding activities (Miyamoto1996HelixLoopHelix). The LYL1-E2a heterodimers have distinctive DNA-binding properties, preferring a specific consensus sequence, 5'-AACAGATG(T/g)T-3', which is different from the binding sites of E2a homodimers (Miyamoto1996HelixLoopHelix).

In endothelial cells, LYL1 forms complexes with TAL1, LMO2, and GATA2, which bind to the promoter region of Angiopoietin-2 (ANG-2), a gene crucial for angiogenesis. These complexes are essential for the transcriptional regulation of ANG-2, with LMO2 playing a critical role in stabilizing the interactions (Deleuze2012Angiopoietin2). LYL1 can also form homodimers, and its interactions with TAL1 and LMO2 are enhanced by GATA2, indicating a complex network of protein interactions that regulate gene expression in both endothelial and hematopoietic cells (Deleuze2012Angiopoietin2).


## References


[1. (Nagel2010Multiple) Stefan Nagel, Letizia Venturini, Corinna Meyer, Maren Kaufmann, Michaela Scherr, Hans G. Drexler, and Roderick A.F. MacLeod. Multiple mechanisms induce ectopic expression of lyl1 in subsets of t-all cell lines. Leukemia Research, 34(4):521–528, April 2010. URL: http://dx.doi.org/10.1016/j.leukres.2009.06.020, doi:10.1016/j.leukres.2009.06.020. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.leukres.2009.06.020)

[2. (Deleuze2012Angiopoietin2) Virginie Deleuze, Rawan El-Hajj, Elias Chalhoub, Christiane Dohet, Valérie Pinet, Philippe Couttet, and Danièle Mathieu. Angiopoietin-2 is a direct transcriptional target of tal1, lyl1 and lmo2 in endothelial cells. PLoS ONE, 7(7):e40484, July 2012. URL: http://dx.doi.org/10.1371/journal.pone.0040484, doi:10.1371/journal.pone.0040484. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0040484)

3. (Choudhury2023InSilico) In-Silico analysis of TAL1, TAL2 and LYL1 gene associated with T-ALL. This article has 0 citations.

[4. (Miyamoto1996HelixLoopHelix) Alison Miyamoto, Xiangmin Cui, Louie Naumovski, and Michael L. Cleary. Helix-loop-helix proteins lyl1 and e2a form heterodimeric complexes with distinctive dna-binding properties in hematolymphoid cells. Molecular and Cellular Biology, 16(5):2394–2401, May 1996. URL: http://dx.doi.org/10.1128/mcb.16.5.2394, doi:10.1128/mcb.16.5.2394. This article has 46 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.16.5.2394)

[5. (Lukov2011The) Georgi L. Lukov, Lara Rossi, George P. Souroullas, Rui Mao, and Margaret A. Goodell. The expansion of t-cells and hematopoietic progenitors as a result of overexpression of the lymphoblastic leukemia gene, lyl1 can support leukemia formation. Leukemia Research, 35(3):405–412, March 2011. URL: http://dx.doi.org/10.1016/j.leukres.2010.07.023, doi:10.1016/j.leukres.2010.07.023. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.leukres.2010.07.023)

[6. (SanMarina2008Lyl1) Serban San-Marina, YouQi Han, Fernando Suarez Saiz, Michael R. Trus, and Mark D. Minden. Lyl1 interacts with creb1 and alters expression of creb1 target genes. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1783(3):503–517, March 2008. URL: http://dx.doi.org/10.1016/j.bbamcr.2007.11.015, doi:10.1016/j.bbamcr.2007.11.015. This article has 24 citations.](https://doi.org/10.1016/j.bbamcr.2007.11.015)

[7. (Chiu2018A) Sung K. Chiu, Jesslyn Saw, Yizhou Huang, Stefan E. Sonderegger, Nicholas C. Wong, David R. Powell, Dominic Beck, John E. Pimanda, Cedric S. Tremblay, and David J. Curtis. A novel role for lyl1 in primitive erythropoiesis. Development, January 2018. URL: http://dx.doi.org/10.1242/dev.162990, doi:10.1242/dev.162990. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.162990)

[8. (Fang2022Superenhancer) Fang Fang, Jun Lu, Xu Sang, Yan-Fang Tao, Jian-Wei Wang, Zi-Mu Zhang, Yong-Ping Zhang, Xiao-Lu Li, Yi Xie, Shui-Yan Wu, Xin-Ran Chu, Gen Li, Di Wu, Yan-Ling Chen, Juan-Juan Yu, Si-qi Jia, Chen-xi Feng, Yuan-Yuan Tian, Zhi-Heng Li, Jing Ling, Shao-Yan Hu, and Jian Pan. Super-enhancer profiling identifies novel critical and targetable cancer survival gene lyl1 in pediatric acute myeloid leukemia. Journal of Experimental &amp; Clinical Cancer Research, July 2022. URL: http://dx.doi.org/10.1186/s13046-022-02428-9, doi:10.1186/s13046-022-02428-9. This article has 10 citations.](https://doi.org/10.1186/s13046-022-02428-9)